Publications and Presentations

Filter By:

ARRY-382

11/01/2013

AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics

A Phase 1 Study of ARRY-382, an Oral Inhibitor of Colony-stimulating Factor-1 Receptor (CSF1R), in Patients with Advanced or Metastatic Cancers

J. Bendell, et al.

Filanesib

10/16/2013

International Society for the Study of Xenobiotics International Meeting

The Role of Alpha 1-Acid Glycoprotein (AAG) as a Selection Marker for ARRY-520 Exposure

K. D. Brown, et al.

Binimetinib

09/30/2013

European Society for Medical Oncology Congress

Results of a phase 1 study of MEK162, an oral MEK inhibitor, in Japanese patients with advanced solid tumors

T. Shimokata, et al.

Encorafenib

07/13/2013

International Melanoma Conference

Initial Results from an Open-label, Dose-escalation Phase I Study of the Oral BRAF Inhibitor LGX818 in BRAF V600-mutant Advanced Melanoma

R. Dummer, et al.

Binimetinib

07/13/2013

International Melanoma Conference

Initial Results from an Open-label, Dose-escalation Phase I Study of the Oral BRAF Inhibitor LGX818 in BRAF V600-mutant Advanced Melanoma

R. Dummer, et al.

Encorafenib

07/12/2013

World Congress of Melanoma

Preliminary Results From a Phase Ib/II, Open-Label, Dose-Escalation Study of the Oral Selective BRAF Inhibitor LGX818 in Combination With the Oral MEK1/2 Inhibitor MEK162 in BRAF V600–Dependent Advanced Solid Tumors

R. Kefford, et al.

Encorafenib

07/12/2013

International Melanoma Conference

Preliminary Results From a Phase Ib/II, Open-Label, Dose-Escalation Study of the Oral Selective BRAF Inhibitor LGX818 in Combination with the Oral MEK1/2 Inhibitor MEK162 in BRAF V600-Dependent Advanced Solid Tumors

R. Kefford, et al.

ASLAN001

06/17/2013

Heterocyclic Compounds GRC

Process Research and Development of the Tyrosine Kinase Inhibitor Varlitinib Tosylate (ARRY-543 Ditosylate)

D. D. Hennings, et al.

Filanesib

06/17/2013

European Hematology Association Annual Congress

ALPHA 1-ACID GLYCOPROTEIN (AAG) IS A POTENTIAL PATIENT SELECTION MARKER FOR CLINICAL ACTIVITY OF ARRY-520 IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA (MM)

B.J. Tunquist, et al.

Filanesib

06/12/2013

European Hematology Association Annual Congress

Phase 1 Study of ARRY-520 and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

J.J. Shah, MD, et al.